| Total | CD20-negative DLBCL(n = 21) | CD20-positive DLBCL (n = 63) | P |
---|---|---|---|---|
Age(years) | Â | Â | Â | Â |
Median (range) | 51.5(9-83) | 53(11-83) | 51(9-71) | 0.955 |
≤60 | 56(66.7%) | 14(66.7%) | 42(66.7) | 1 |
Sex | Â | Â | Â | Â |
Male | 64(76.2%) | 16(76.2%) | 48(76.2%) | 1 |
Female | 20(23.8%) | 5(23.8%) | 15(23.8%) | Â |
PS score | Â | Â | Â | Â |
0-1 | 75(89.3%) | 18(85.7%) | 57(90.5%) | 0.839 |
≥2 | 9(10.7%) | 3(14.3%) | 6(9.5%) |  |
Stage | Â | Â | Â | Â |
I-II | 49(58.3%) | 12(57.1%) | 37(58.7%) | 0.898 |
III-IV | 35(41.7%) | 9(42.9%) | 26(41.3%) | Â |
LDH | Â | Â | Â | Â |
Normal | 50(59.5%) | 14(66.7%) | 36(57.1%) | 0.441 |
Elevated | 34(40.5%) | 7(33.3%) | 27(42.9%) | Â |
Extranodal sites | Â | Â | Â | Â |
0-1 | 73(86.9%) | 16(76.2%) | 57(90.5%) | 0.191 |
≥2 | 11(13.1%) | 5(23.8%) | 6(9.5%) |  |
IPI | Â | Â | Â | Â |
0-1 | 44(52.4%) | 11(52.4%) | 33(52.4%) | 1 |
2-3 | 40(47.6%) | 10(47.6%) | 30(47.6%) | Â |
Bulky disease | Â | Â | Â | Â |
Yes | 20(23.8%) | 8(38.1%) | 12(19%) | 0.076 |
No | 64(76.2%) | 13(61.9%) | 51(81%) | Â |
BM involvement | Â | Â | Â | Â |
Yes | 2(2.4%) | 2(9.5%) | 0(0) | 0.06 |
No | 82(97.6%) | 19(90.5%) | 63(100%) | Â |
B symptom | Â | Â | Â | Â |
Present | 23(27.4%) | 8(38.1%) | 15(23.8%) | 0.204 |
Absent | 61(72.6%) | 13(61.9%) | 48(76.2%) | Â |
First-line chemotherapy | Â | Â | Â | Â |
CHOP or CHOP-like | 79(94%) | 20(95.2%) | 59(93.7%) | 1 |
Other regimens | 5(6%) | 1(4.8%) | 4(6.3%) | Â |
Radiotherapy | Â | Â | Â | Â |
Yes | 28(33.3%) | 5(23.8%) | 23(36.5%) | 0.285 |
No | 56(66.7%) | 16(76.2%) | 40(63.5%) | Â |
Surgery | Â | Â | Â | Â |
Yes | 11(13.1%) | 5(23.8%) | 6(9.5%) | 0.191 |
No | 73(86.9%) | 16(76.2%) | 57(90.5%) | Â |
Autologous SCT | Â | Â | Â | Â |
Yes | 4(4.8%) | 1(4.8%) | 3(4.8%) | 1 |
No | 80(95.2%) | 20(95.2%) | 60(95.2%) | Â |
Follow-up (months) | Â | Â | Â | Â |
Median (range) | 41.5(2-121) | 13(3-117) | 47(2-121) | Â |